Back to top
more

Supernus Pharmaceuticals (SUPN)

(Real Time Quote from BATS)

$32.14 USD

32.14
83,503

+0.08 (0.25%)

Updated Oct 8, 2024 12:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 16% (40 out of 252)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 28.7% upside potential for Supernus (SUPN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates

by Zacks Equity Research

Supernus (SUPN) delivered earnings and revenue surprises of -2.70% and 13.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Select Medical (SEM) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Select Medical (SEM) delivered earnings and revenue surprises of 1.69% and 1.63%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Supernus (SUPN) stock based on the movements in the options market lately.

Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Supernus (SUPN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.

Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates

by Zacks Equity Research

Supernus (SUPN) delivered earnings and revenue surprises of -95.12% and 6.39%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Supernus (SUPN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -1.05% and 74.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Supernus (SUPN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Supernus Pharmaceuticals (SUPN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Supernus (SUPN) delivered earnings and revenue surprises of -323.08% and 8.74%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Supernus (SUPN) delivered earnings and revenue surprises of -108.70% and 6.64%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Bausch (BHC) delivered earnings and revenue surprises of 8% and 6.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Generation Bio Co. (GBIO) delivered earnings and revenue surprises of 4.08% and 88.27%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Supernus (SUPN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Supernus (SUPN) delivered earnings and revenue surprises of 141.67% and 8.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

BridgeBio Pharma (BBIO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -9.52% and 74.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) Q4 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Supernus (SUPN) delivered earnings and revenue surprises of -41.10% and 8.15%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Supernus Pharmaceuticals (SUPN) Misses Q3 Earnings Estimates

by Zacks Equity Research

Supernus (SUPN) delivered earnings and revenue surprises of -90.63% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?